+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anticonvulsants Market by Drug Class (Benzodiazepines, Carbonic Anhydrase Inhibitors, Gaba Analogues), Indication (Bipolar Disorder, Epilepsy, Migraine Prophylaxis), Route Of Administration, Distribution Channel - Global Forecast 2025-2030- Product Image
Anticonvulsants Market by Drug Class (Benzodiazepines, Carbonic Anhydrase Inhibitors, Gaba Analogues), Indication (Bipolar Disorder, Epilepsy, Migraine Prophylaxis), Route Of Administration, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Anticonvulsants Market by Drug Class (Benzodiazepines, Carbonic Anhydrase Inhibitors, Gaba Analogues), Indication (Bipolar Disorder, Epilepsy, Migraine Prophylaxis), Route Of Administration, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 181 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5305569
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The global anticonvulsants market is rapidly evolving as clinical innovation, digital health technologies, and policy changes transform product adoption and competitive dynamics. Senior decision-makers face new challenges and opportunities as the industry shifts toward patient-centric and precision therapies.

Market Snapshot: Anticonvulsants Market Size and Trend Overview

The anticonvulsants market grew from USD 13.07 billion in 2024 to USD 14.23 billion in 2025. It is expected to continue growing at a CAGR of 8.74%, reaching USD 21.61 billion by 2030. Factors influencing this growth include ongoing advancements in neuroscience, broader clinical adoption for neurological and psychiatric indications, and expanding real-world evidence supporting diverse product pipelines. Mergers among pharma leaders and new digital health integrations are also shaping treatment access and delivery. Market expansion varies across regions due to macroeconomic factors, regulatory timelines, and supply chain shifts.

Scope & Segmentation of the Anticonvulsants Market

This research provides a detailed breakdown of the anticonvulsants market, covering all major product, route, and regional categories to inform investment and go-to-market strategies.

  • Drug Classes: Includes benzodiazepines (clobazam, clonazepam, diazepam), carbonic anhydrase inhibitors (acetazolamide, methazolamide), GABA analogues (gabapentin, pregabalin, vigabatrin), sodium channel blockers (carbamazepine, lamotrigine, phenytoin), and SV2A modulators (brivaracetam, levetiracetam).
  • Indications: Addresses epilepsy (absence, focal, generalized, myoclonic seizures, status epilepticus), bipolar disorder (type I, type II), migraine prophylaxis, and neuropathic pain (diabetic neuropathy, postherpetic neuralgia).
  • Routes of Administration: Oral, injectable, rectal, and transdermal formulations, with applicability for both chronic and acute seizure control.
  • Distribution Channels: Drug stores, hospital pharmacies, online pharmacies, and retail outlets for both acute and maintenance regimens.
  • Regional Coverage: Includes the Americas (notably United States regions such as California, Texas, New York, and others; plus Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (with significant countries including the United Kingdom, Germany, France, Russia, and others in GCC and Africa), and Asia-Pacific (including China, India, Japan, Australia, South Korea, Southeast Asia).
  • Leading Companies: Features Pfizer Inc., Eisai Co., Novartis AG, AbbVie, Johnson & Johnson Services, Sanofi S.A., Teva Pharmaceutical Industries, Viatris, and GlaxoSmithKline.

Key Takeaways for Senior Decision-Makers

  • Growth in patient-centered therapies is linked to advances in formulation science, such as sustained-release and transdermal options that improve adherence and diversify delivery.
  • Precision medicine and digital health technologies, including mobile tracking and AI-powered safety monitoring, are increasing the personalization and safety of anticonvulsant regimens.
  • Expansion across dual domains, including mood stabilization and pain management, is broadening the addressable market for both established and new drug classes.
  • Alliances between biotech firms and pharma multinationals are facilitating agile clinical development, co-manufacturing efficiencies, and resilient supply chains amid ongoing volatility.
  • Nuanced regulatory changes are emphasizing real-world evidence generation and lifecycle management, impacting approval pathways and reimbursement decisions.
  • Regional heterogeneity in demand, pricing, and access requires adaptive go-to-market strategies tailored for local payer systems and evolving regulatory requirements.

Anticonvulsants Market: Assessing Tariff Impact

Recent US tariff policy changes have increased duties on imported active pharmaceutical ingredients and key materials, prompting manufacturers to diversify supplier networks and localize select production capabilities. This trend accelerates co-manufacturing partnerships and logistical redesigns, especially for generic portfolios with tight margins. Strategies to absorb higher input costs are particularly critical for maintaining access and pricing competitiveness across target geographies. Engagement with industry associations and government is ongoing to seek exemptions on essential ingredients.

Methodology & Data Sources

This analysis uses a rigorous methodological framework, synthesizing primary research from structured stakeholder interviews across clinical, supply chain, and regulatory domains, and secondary research from journals, filings, patent databases, and white papers. Data triangulation, cross-checking with government trade reports, peer review of models, and subject matter expert validation underpin the accuracy, reliability, and transparency of findings.

Why This Report Matters for the Anticonvulsants Market

  • Enables stakeholders to anticipate market shifts and chart response strategies for pricing, procurement, and supply chain management as macroeconomic and policy factors evolve.
  • Supports resource allocation and R&D direction by providing actionable segmentation insights aligned with real-world clinical demand and regional differences in access and infrastructure.
  • Strengthens the ability to align internal initiatives across regulatory, commercial, and innovation functions using unbiased, methodologically validated market intelligence.

Conclusion

The anticonvulsants market is at a turning point, shaped by new therapeutic innovations, digital integration, and complex regulatory environments. Strategic adaptation and cross-industry collaboration will determine long-term competitive advantage as industry participants respond to evolving patient and health system needs.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Growing adoption of personalized medicine approaches in epilepsy treatment to enhance efficacy and tolerability
5.2. Increased investment and clinical trials for novel sodium channel blockers targeting focal-onset seizures in adults
5.3. Rising use of cannabidiol-based therapeutic formulations following major regulatory approvals and positive trial outcomes
5.4. Emergence of extended-release anticonvulsant formulations aimed at improving patient adherence and minimizing side effect profiles
5.5. Integration of digital health platforms and wearable seizure detection devices for remote monitoring and data-driven intervention
5.6. Expanding pipeline of next-generation GABA receptor modulators designed to address treatment-resistant epilepsy populations
5.7. Strategic collaborations between pharmaceutical companies and academic research centers to accelerate anticonvulsant innovation
5.8. Growing penetration of low-cost generic anticonvulsant drugs in emerging markets driven by recent patent expirations
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Anticonvulsants Market, by Drug Class
8.1. Introduction
8.2. Benzodiazepines
8.2.1. Clobazam
8.2.2. Clonazepam
8.2.3. Diazepam
8.3. Carbonic Anhydrase Inhibitors
8.3.1. Acetazolamide
8.3.2. Methazolamide
8.4. Gaba Analogues
8.4.1. Gabapentin
8.4.2. Pregabalin
8.4.3. Vigabatrin
8.5. Sodium Channel Blockers
8.5.1. Carbamazepine
8.5.2. Lamotrigine
8.5.3. Phenytoin
8.6. Sv2A Modulators
8.6.1. Brivaracetam
8.6.2. Levetiracetam
9. Anticonvulsants Market, by Indication
9.1. Introduction
9.2. Bipolar Disorder
9.2.1. Type I
9.2.2. Type II
9.3. Epilepsy
9.3.1. Absence Seizures
9.3.2. Focal Seizures
9.3.3. Generalized Seizures
9.3.4. Myoclonic Seizures
9.3.5. Status Epilepticus
9.4. Migraine Prophylaxis
9.5. Neuropathic Pain
9.5.1. Diabetic Neuropathy
9.5.2. Postherpetic Neuralgia
10. Anticonvulsants Market, by Route Of Administration
10.1. Introduction
10.2. Injectable
10.3. Oral
10.4. Rectal
10.5. Transdermal
11. Anticonvulsants Market, by Distribution Channel
11.1. Introduction
11.2. Drug Stores
11.3. Hospital Pharmacy
11.4. Online Pharmacy
11.5. Retail Pharmacy
12. Americas Anticonvulsants Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Anticonvulsants Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Anticonvulsants Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Pfizer Inc.
15.3.2. Eisai Co., Ltd.
15.3.3. Novartis AG
15.3.4. AbbVie Inc.
15.3.5. Johnson & Johnson Services, Inc.
15.3.6. Sanofi S.A.
15.3.7. Teva Pharmaceutical Industries Ltd.
15.3.8. Viatris Inc.
15.3.9. GlaxoSmithKline plc
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. ANTICONVULSANTS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ANTICONVULSANTS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ANTICONVULSANTS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. ANTICONVULSANTS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. ANTICONVULSANTS MARKET: RESEARCHAI
FIGURE 24. ANTICONVULSANTS MARKET: RESEARCHSTATISTICS
FIGURE 25. ANTICONVULSANTS MARKET: RESEARCHCONTACTS
FIGURE 26. ANTICONVULSANTS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ANTICONVULSANTS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTICONVULSANTS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ANTICONVULSANTS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CLOBAZAM, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CLOBAZAM, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CLONAZEPAM, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CLONAZEPAM, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DIAZEPAM, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DIAZEPAM, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ACETAZOLAMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ACETAZOLAMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ANTICONVULSANTS MARKET SIZE, BY METHAZOLAMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ANTICONVULSANTS MARKET SIZE, BY METHAZOLAMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GABAPENTIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GABAPENTIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ANTICONVULSANTS MARKET SIZE, BY PREGABALIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ANTICONVULSANTS MARKET SIZE, BY PREGABALIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ANTICONVULSANTS MARKET SIZE, BY VIGABATRIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ANTICONVULSANTS MARKET SIZE, BY VIGABATRIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBAMAZEPINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBAMAZEPINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ANTICONVULSANTS MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ANTICONVULSANTS MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ANTICONVULSANTS MARKET SIZE, BY PHENYTOIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ANTICONVULSANTS MARKET SIZE, BY PHENYTOIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BRIVARACETAM, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BRIVARACETAM, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ANTICONVULSANTS MARKET SIZE, BY LEVETIRACETAM, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ANTICONVULSANTS MARKET SIZE, BY LEVETIRACETAM, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ANTICONVULSANTS MARKET SIZE, BY TYPE I, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ANTICONVULSANTS MARKET SIZE, BY TYPE I, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ANTICONVULSANTS MARKET SIZE, BY TYPE II, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ANTICONVULSANTS MARKET SIZE, BY TYPE II, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ABSENCE SEIZURES, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ABSENCE SEIZURES, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ANTICONVULSANTS MARKET SIZE, BY FOCAL SEIZURES, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ANTICONVULSANTS MARKET SIZE, BY FOCAL SEIZURES, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GENERALIZED SEIZURES, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GENERALIZED SEIZURES, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ANTICONVULSANTS MARKET SIZE, BY MYOCLONIC SEIZURES, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ANTICONVULSANTS MARKET SIZE, BY MYOCLONIC SEIZURES, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ANTICONVULSANTS MARKET SIZE, BY STATUS EPILEPTICUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ANTICONVULSANTS MARKET SIZE, BY STATUS EPILEPTICUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ANTICONVULSANTS MARKET SIZE, BY MIGRAINE PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ANTICONVULSANTS MARKET SIZE, BY MIGRAINE PROPHYLAXIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL ANTICONVULSANTS MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL ANTICONVULSANTS MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL ANTICONVULSANTS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL ANTICONVULSANTS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL ANTICONVULSANTS MARKET SIZE, BY RECTAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL ANTICONVULSANTS MARKET SIZE, BY RECTAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL ANTICONVULSANTS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL ANTICONVULSANTS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG STORES, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL ANTICONVULSANTS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL ANTICONVULSANTS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL ANTICONVULSANTS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL ANTICONVULSANTS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 163. CANADA ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 164. CANADA ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 165. CANADA ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2024 (USD MILLION)
TABLE 166. CANADA ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2025-2030 (USD MILLION)
TABLE 167. CANADA ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 168. CANADA ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 169. CANADA ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2024 (USD MILLION)
TABLE 170. CANADA ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2025-2030 (USD MILLION)
TABLE 171. CANADA ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 172. CANADA ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 173. CANADA ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2024 (USD MILLION)
TABLE 174. CANADA ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2025-2030 (USD MILLION)
TABLE 175. CANADA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 176. CANADA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 177. CANADA ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2024 (USD MILLION)
TABLE 178. CANADA ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2025-2030 (USD MILLION)
TABLE 179. CANADA ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2024 (USD MILLION)
TABLE 180. CANADA ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2025-2030 (USD MILLION)
TABLE 181. CANADA ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 182. CANADA ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 183. CANADA ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 184. CANADA ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 185. CANADA ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 186. CANADA ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 187. MEXICO ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 188. MEXICO ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 189. MEXICO ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2024 (USD MILLION)
TABLE 190. MEXICO ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2025-2030 (USD MILLION)
TABLE 191. MEXICO ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 192. MEXICO ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 193. MEXICO ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2024 (USD MILLION)
TABLE 194. MEXICO ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2025-2030 (USD MILLION)
TABLE 195. MEXICO ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 196. MEXICO ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 197. MEXICO ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2024 (USD MILLION)
TABLE 198. MEXICO ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2025-2030 (USD MILLION)
TABLE 199. MEXICO ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 200. MEXICO ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 201. MEXICO ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2024 (USD MILLION)
TABLE 202. MEXICO ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2025-2030 (USD MILLION)
TABLE 203. MEXICO ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2024 (USD MILLION)
TABLE 204. MEXICO ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2025-2030 (USD MILLION)
TABLE 205. MEXICO ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 206. MEXICO ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 207. MEXICO ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 208. MEXICO ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 209. MEXICO ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 210. MEXICO ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2025-2030 (USD MILLION)
TABLE 219. BRAZIL ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 220. BRAZIL ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 221. BRAZIL ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2024 (USD MILLION)
TABLE 222. BRAZIL ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2025-2030 (USD MILLION)
TABLE 223. BRAZIL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 224. BRAZIL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 225. BRAZIL ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2024 (USD MILLION)
TABLE 226. BRAZIL ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2025-2030 (USD MILLION)
TABLE 227. BRAZIL ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2024 (USD MILLION)
TABLE 228. BRAZIL ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2025-2030 (USD MILLION)
TABLE 229. BRAZIL ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 230. BRAZIL ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 231. BRAZIL ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 232. BRAZIL ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 233. BRAZIL ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 234. BRAZIL ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 235. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 236. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2025-2030 (USD MILLION)
TABLE 239. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 240. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 241. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2024 (USD MILLION)
TABLE 242. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2025-2030 (USD MILLION)
TABLE 243. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 244. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 245. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2024 (USD MILLION)
TABLE 246. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2025-2030 (USD MILLION)
TABLE 247. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 248. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 249. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2024 (USD MILLION)
TABLE 250. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2025-2030 (USD MILLION)
TABLE 251. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2024 (USD MILLION)
TABLE 252. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2025-2030 (USD MILLION)
TABLE 253. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 254. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 255. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 256. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 257. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 258. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2024 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2025-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2024 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2025-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2024 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2025-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2024 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2025-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2024 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2025-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 279. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 281. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 285. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 286. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 287. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2024 (USD MILLION)
TABLE 288. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2025-2030 (USD MILLION)
TABLE 289. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 290. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 291. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2024 (USD MILLION)
TABLE 292. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2025-2030 (USD MILLION)
TABLE 293. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 294. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 295. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2024 (USD MILLION)
TABLE 296. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2025-2030 (USD MILLION)
TABLE 297. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 298. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 299. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2024 (USD MILLION)
TABLE 300. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2025-2030 (USD MILLION)
TABLE 301. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2024 (USD MILLION)
TABLE 302. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2025-2030 (USD MILLION)
TABLE 303. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 304. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 305. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 306. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 307. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 308. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 309. GERMANY ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 310. GERMANY ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 311. GERMANY ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2024 (USD MILLION)
TABLE 312. GERMANY ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2025-2030 (USD MILLION)
TABLE 313. GERMANY ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 314. GERMANY ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 315. GERMANY ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2024 (USD MILLION)
TABLE 316. GERMANY ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2025-2030 (USD MILLION)
TABLE 317. GERMANY ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 318. GERMANY ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 319. GERMANY ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2024 (USD MILLION)
TABLE 320. GERMANY ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2025-2030 (USD MILLION)
TABLE 321. GERMANY ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 322. GERMANY ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 323. GERMANY ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2024 (USD MILLION)
TABLE 324. GERMANY ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2025-2030 (USD MILLION)
TABLE 325. GERMANY ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2024 (USD MILLION)
TABLE 326. GERMANY ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2025-2030 (USD MILLION)
TABLE 327. GERMANY ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 328. GERMANY ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 329. GERMANY ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 330. GERMANY ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 331. GERMANY ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 332. GERMANY ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 333. FRANCE ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 334. FRANCE ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 335. FRANCE ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2024 (USD MILLION)
TABLE 336. FRANCE ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2025-2030 (USD MILLION)
TABLE 337. FRANCE ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 338. FRANCE ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 339. FRANCE ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2024 (U

Samples

Loading
LOADING...

Companies Mentioned

  • Pfizer Inc.
  • Eisai Co., Ltd.
  • Novartis AG
  • AbbVie Inc.
  • Johnson & Johnson Services, Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • GlaxoSmithKline plc

Table Information

Report AttributeDetails
No. of Pages181
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 14.23 Billion
Forecasted Market Value ( USD ) by 2030 $ 21.61 Billion
Compound Annual Growth Rate8.7%
Regions CoveredGlobal
No. of Companies Mentioned9

Related Topics

Related Reports

Anticonvulsants Market Report 2025 - Product Image

Anticonvulsants Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Neuropathic Pain Drug Market by Product Type (Anticonvulsants, Antidepressants, Opioids), Route Of Administration (Intravenous, Oral, Topical), Indication, Distribution Channel - Global Forecast 2025-2030 - Product Image

Neuropathic Pain Drug Market by Product Type (Anticonvulsants, Antidepressants, Opioids), Route Of Administration (Intravenous, Oral, Topical), Indication, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
Diabetic Neuropathy Market by Drug Class (Anticonvulsants, Opioids, Snris), Route Of Administration (Oral, Parenteral, Topical), Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Diabetic Neuropathy Market by Drug Class (Anticonvulsants, Opioids, Snris), Route Of Administration (Oral, Parenteral, Topical), Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
Central Nervous System Therapeutics Market Size, Share & Trends Analysis Report by Disease, Drug Class (Anticonvulsants, CNS Stimulants), Distribution Channel, Region, and Segment Forecasts, 2025-2030 - Product Image

Central Nervous System Therapeutics Market Size, Share & Trends Analysis Report by Disease, Drug Class (Anticonvulsants, CNS Stimulants), Distribution Channel, Region, and Segment Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
West Syndrome Global Market Report 2025 - Product Image

West Syndrome Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From

About the Anticonvulsants Market

Anticonvulsants are a class of drugs used to treat seizures and other neurological disorders. They work by reducing the abnormal electrical activity in the brain that causes seizures. Anticonvulsants are used to treat a variety of conditions, including epilepsy, bipolar disorder, and neuropathic pain. They are also used to prevent seizures in people with certain types of brain injuries. Anticonvulsants are part of the larger class of Central Nervous System (CNS) drugs, which also includes antidepressants, antipsychotics, and anxiolytics. The anticonvulsant market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, GlaxoSmithKline, Novartis, Sanofi, and Johnson & Johnson. Other companies include Mylan, Teva Pharmaceuticals, and Sun Pharmaceuticals. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.